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CD34+ STEM CELL SELECTION AND CD3+ ADDBACK FOR PEDIATRIC PA-
TIENTS RECEIVING MATCHED UNRELATED ADULT DONOR (MUD) PE-
RIPHERAL BLOOD STEM CELL TRANSPLANTATION (PBSCT) IS
ASSOCIATED WITH RAPID MYELOID ENGRAFTMENT AND LOW RISK OF
BOTH POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD)
AND GRADE 2-4 ACUTE GRAFT VERSUS HOST DISEASE (AGVHD)
Geyer, M.B.1, Jacobson, J.S.2, Fearon, N.1, Satwani, P.1, Bhatia, M.1,
George, D.1, Bradley, M.B.1, Garvin, J.H.1, Harrison, L.1, Morris, E.1,
Fanelli, C.1, Semidei-Pomales, M.3, Daniel-Johnson, J.A.3, Schwartz, J.3,
Baxter-Lowe, L.A.4, Cairo, M.S.1,3,5 1Morgan Stanley Children’s Hospital,
New York-Presbyterian Hospital, Columbia University, NY; 2Columbia
University,NewYork,NY; 3ColumbiaUniversity,NewYork,NY; 4Univer-
sity of California, San Francisco, CA; 5Columbia University, New York, NY
Background: Positive selection of CD34 stem cells is a method of
depletion of T cells responsible for severe aGVHD (Lang et al.,
Blood, 2003). CD34-selected haploidentical SCT in children with
leukemia and nonmalignant diseases is associated with sustained en-
graftment and low risk of aGVHD (Lang/Handgretinger, BMT,
2008). Myeloablative conditioning (MAC) followed by CD34-se-
lected MUD PBSCT with a CD3 dose of 5105/kg carries high
risk of chronic GVHD (Bunin et al., BMT, 2006). We sought to de-
termine engraftment, survival, immune reconstitution (IR) and fre-
quency of PTLD and GVHD in pediatric patients at risk of severe
aGVHD following CD34-selected MUD PBSCT.
Methods: The Isolex 300i (Nexell, Irvine, CA) immunomagnetic
cell selection system was used for CD34 selection with a goal of
achieving$5 x106 CD34/kg PBSC. T cells were added back to reach
a total CD3 dose of 1.0-2.6105/kg. Conditioning wasMAC in 57%
vs. reduced intensity (RIC) in 43%. GVHD prophylaxis consisted
only of tacrolimus. Supportive care was as we have previously de-
scribed (Bradley/Cairo, BMT, 2007).
Results: Fourteen pts, median f/u of 451 d, median age of 15.0 yrs
(10-23); 1:1 M:F, HLA match 29% 10/10, 36% 9/10, 26% 8/10,
64% malignant (56/44% poor/average risk). Cell selection resulted
in median CD34 recovery of 59% and 4.33 CD3 log depletion
(Table 1).
All 14 pts engrafted neutrophils (median day 14, range 9-27).
Of 12 evaluable pts, 10 (83%) engrafted platelets (median day
32, range 21-44). No pts developed PTLD. One pt (7%) devel-
oped CMV infection. Probabilities of grade II-IV aGVHD and
chronic GVHD were 14.3% (95% CI 0-31%) and 36.4% (1-
59%) respectively. Day 100 mortality was 7%. The probability
of 1-year OS was 84% (67-100%). Of 9 pts with acute leukemia,
3 (33%) died from progressive disease. CD3, CD4, CD8, CD19
and CD56 counts at day +180/365 were normal in 20/38%, 0/
13%, 40/63%, 70/100% and 100/100% of pts, respectively. En-
graftment, GVHD, fungal infection and IR did not differ with
respect to conditioning; MAC recipients had higher risk of viral
infection (p5 .02) and mortality (5/8 in MAC vs. 0/6 in RTC,
but p5 .09)
Conclusions: Rapid neutrophil engraftment, no PTLD, minimal
grade II-IV aGVHD and high day 100 and overall survival were ob-
served. Depletion of B and T cells during CD34 selection may be re-
sponsible for the relatively slow recovery of T cells post-transplant.
These results support the continued investigation of CD34-selected
MUD PBSCT in pediatric recipients.
Table 1. Stem cell selection data for patients undergoing
CD341-selected MUD PBSCT
Median RangePre-Selection CD341 x 106 total cells 438.79 239.75 - 886.41
Post-Selection CD341 x 106 total cells 299.57 131.81 - 521.94
CD341 Percent Recovery 58.88 42.93 - 85.58
Final Infused CD341 x 106/kg 5.06 2.02 - 13.30
Pre-Selection CD31 x 108/kg 4.74 2.30 - 20.69
Post-Selection CD31 x 105/kg 0.220 \0.001 - 2.450
CD31 Log Depletion 4.33 2.45 - *
CD31 Addback x 105/kg 1.003 0 - 2.170
Final Infused CD31 x 105/kg 1.500 0.093 - 2.600*Post-selection CD31 was below the threshold of detection for two grafts.242
ANALYSIS OF THE INCIDENCE AND CHARACTERISTICS OF VENOOCCLU-
SIVE DISEASE (VOD) OF THE LIVER IN PEDIATRIC HEMATOPOIETIC PRO-
GENITOR CELL TRANSPLANT (HPCT) PATIENTS WITH HEPARIN ALONE
VS. HEPARIN AND URSODIOL PROPHYLAXIS AT THE MEDICAL COLLEGE
OF WISCONSIN
Talano, J.M.1, Brown, J.1, Casper, J.T.1, Mulberry, M.1, Eastwood, D.2,
Ahn, K.W.2, Margolis, D.A.1 1Medical College of Wisconsin, Milwaukee,
WI; 2Medical College of Wisconsin, Milwaukee, WI
VOD is a serious and potentially life-threatening complication of
HPCT as a result of liver injury from the effect of chemotherapy
and/or radiation. The reported incidence rate in pediatric HPCT
patients varies widely from 5% to 40%. Previous studies have shown
the beneficial effects of post-transplant pharmacological therapies
such as ursodeoxyholic acid (ursodiol), heparin, and defibrotide at
preventing VOD. However, the combined effect of heparin and ur-
sodiol prophylaxis in preventing VOD in pediatric patients has yet to
be determined. This study evaluated retrospectively whether there
was a benefit of such combined therapy in pediatric HPCT patients.
Our center adopted as standard practice for all HPCT patients the
initiation of low dose heparin at 4 units/kg/hour with the commence-
ment of conditioning for HPCT until day +28 post transplant. In
2003, we combined ursodiol 10 mg/kg TID to start with HPCT
conditioning and to continue until day + 100 post transplant with
low dose heparin through day + 28 for all pediatric HPCT patients.
We performed a retrospective chart review and compared the
characteristics and the incidence of VOD in patients who underwent
transplantation from 1996-2002 and received heparin alone com-
pared to 2003-2008 when the patients received the combination of
heparin and ursodiol prophylaxis. Patients were identified through
medical records with the ICD diagnosis of VOD. The medical re-
cords were reviewed and those patients who did not meet the Balti-
more criteria for the diagnosis of VODwere excluded. Only patients
who developed VOD with their first transplants were included.
The 100 day incidence of VODwas 0.0605 (SE 0.01618) in group
1 and 0.0227 (SE 0.01002) in group 2. The difference is 0.0377 (SE
0.0190) and based on a standard normal distribution with
a p5 0.0473. The day 100 survival in the VOD patients was 6 out
of 13 in group 1 and 3 out of 5 in group 2. In conclusion, low dose
heparin and ursodiol prophylaxis appears to be an effective strategy
in VOD prevention in pediatric patients. The combination appeared
to be more effective than heparin alone. However, this study is lim-
ited in that it is retrospective in nature. Future prospective trials need
to be performed in pediatric HPCT patients to further elucidate the
most efficacious and cost effective VOD prophylaxis, since currently
there is no consensus of what constitutes standard of care among pe-
diatric HPCT centers.
Group 1 Heparin Group 2 Heparin
(216) 1Ursodiol (220)Allogeneic 187 (86.5%) 160 (72.7%)
Autologous 29 (13.5%) 60 (27.3%)
Median Age 9 yrs 8 yrs
Male 123 (57%) 135 (62%)Non-malignant 34 (15.7%) 50 (22.8%)
Hematologic Malignancy 143 (66.2%) 109 (49.5%)
Non-hematologic Malignancy 39 (18.1%) 61 (27.7%)
# VOD 13 5243
OUTCOMES OF MATCHED RELATED DONOR HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN PEDIATRIC PATIENTS WITH MYELODYSPLASTIC
SYNDROME
Parikh, S.H., Martin, P.L., Prasad, V.K., Szabolcs, P., Ciocci, G.,
Driscoll, T.A., Kurtzberg, J. Duke University Medical Center, Durham,
NC
Myelodysplastic syndromes (MDS) in children are associated with
significant morbidity and risk of leukemic transformation. Alloge-
neic hematopoietic stem cell transplantation is the only curative
therapy. The ideal allogeneic donor is an HLA-identical sibling or
Poster Session I S249relative orMatchedRelatedDonor (MRD). From1990 to 2007, a to-
tal of 15 pediatric or young adult patients with MDS received bone
marrow or cord blood transplant from an HLA matched sibling at
our institution. M:F ratio of the study group was 0.9; Two patients
belonged to ethnic minorities (13%); the median age at transplant
was 13.4 years (range 1.1-20.6) and median weight was 54.9 kg
(range 10.8-80.2). Three patients had therapy-related MDS (2
ALL, 1 NHL). MDS stage was RA/RC in 2 pts, RARS in 1 pt,
RAEB in 6 pts, RAEB-T in 2 pts, and AML in 4 pts. Monosomy 7
was present in 4 (27%) pts. Median time from diagnosis to transplant
was 3 months (range 1.3-25.8). Preparative regimen was non-TBI
based in 13 (87%) pts. TBI was used for 2 of the patients with
AML. Fourteen (93%) patients received melphalan. Cyclosporine
was used for GVHD prophylaxis with methotrexate in 12 pts and
Solu-medrol in 2 pts. The grafts (14 BM, 1UCB) contained amedian
of 2  10e8 (range 0.7-8.4) nucleated cells/kg infused. All patients
achieved neutrophil engraftment. Median time to neutrophil recov-
ery (ANC. 500) was 17 days (range 10-33), and that to platelet re-
covery (.50 K untransfused) was 43 days (range 21-150). Acute
GVHD, grade II-IV, was seen in 6 (40%) patients; none of the pa-
tients had grade III-IV acute GVHD. Chronic GVHD was seen in
4 (27%) patients, 2 limited (skin), and 2 extensive (skin, gut). The
only patient with RARS died from lactic acidosis secondary to
MELAS syndrome diagnosed post mortem. One patient, who had
undergone a prior transplant for ALL, acquired monosomy 7 clone
40months later. She underwent BMT from the same donor, relapsed
again after 22 months, underwent a third successful transplant from
the same donor with non-myeloablative conditioning and peripheral
blood stem cells. She is disease free 8 years from the last transplant.
Thus, 14 (93.3%) of the 15 patients are surviving long term and dis-
ease free with a median follow-up of 8.5 years (range 2.3-19). Bone
marrow or cord blood transplant from matched related donor with
non-TBI based, melphalan containing regimen is very effective in
curing MDS affecting children and young adults.244
HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR DNA-DSB RE-
PAIR DEFECTS USING A MODIFIED FANCONI ANAEMIA CONDITIONING
REGIMEN
Slatter, M.1, Barge, D.2, Jeggo, P.3, Nademi, Z.1, Harvey, H.1, Flood, T.1,
Cant, A.1, Hambleton, S.1, Abinun, M.1, Gennery, A.1 1Newcastle upon
Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United King-
dom; 2Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle
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Lymphocyte receptor generation requires proteins in the DNA-
double strand break (DNA-dsb) repair and non-homologous end-
joining pathway. Nibrin senses DNA-dsb, DNA ligase IV (LIG4)
and Cernunnos-XRCC4-like factor (C-XLF) ligate DNA-dsb to
form lymphocyte receptors, as well as general DNA-dsb repair. De-
ficiency of these enzymes confers radiosensitivity (RS) and primary
immunodeficiency (PID). Patients with PID due to deficiencies in
these genes are increasingly offered HSCT. Many conditioning reg-
imens (CR) damage DNA and RS patients die from CR toxicity; less
toxic CR are required to successfully treat these patients. We report
3 microcephalic RS patients treated using a modified Fanconi anae-
mia CR of C-1H 0.2 mg/KgD-9 –D-5, fludarabine 30 mg/m2D-9 –
D-5, cyclophosphamide 5 mg/kg D-5-D-2.
Patient 1 presented with prolonged RSV excretion. She had pan-
lymphopenia with marked CD8 lymphopenia, reduced PHA re-
sponse andpan-hypogammaglobulinaemiawith poor vaccine antigen
antibody responses. A homozygous 1089C.A mutation in NBS1
confirmed Nijmegen breakage syndrome. She underwent HLA-
identical sibling HSCT age 2 years. At 5 years post-HSCT she has
stable mixed donor chimerism in all cell lineages, with normal lym-
phocyte numbers and antibody responses to vaccine antigens.
Patient 2 presented with failure to thrive, persistent diarrhoea, re-
current respiratory infection and severe lymphopenia with hypogam-
maglobulinaemia. She had a homozygous c.833 G.A LIG4
mutation. She underwent a 9/10 (Amm) HLAmis-matched parental
HSCT aged 4.5 years. CSA and MMF were used as GvHD prophy-
laxis. Initial donor chimerism was 12%, but by 1 year post-HSCT
was 100% with full immunoreconstitution.
Patient 3 presentedwith developmental delay, severe lymphopenia
and hypogammaglobulinaemia, recurrent respiratory infection andcytomegaloviremia (CMV). He had a homozygous c.169C.Tmu-
tation in NHEJ1, confirming C-XLF deficient PID. He underwent
9/10 (Amm) HLA-mis-matched URD HSCT aged 3.5 years. CSA
andMMF were used as GvHD prophylaxis. Initial donor chimerism
was 25%, but by 2months postHSCTwas 100%.There was no con-
ditioning-related toxicity and immunoreconstitution at 4 months
was 100% donor. Subsequent complications included CMV reacti-
vation and skin and liver GvHD, from which he died at 358 days
post-HSCT. These, and a survey of other cases, demonstrate safety
and efficacy of this conditioning protocol. Further studies will be re-
quired to assess the long term outcome.245
PEDIATRIC AUTOLOGOUS PERIPHERAL BLOOD STEM CELL HARVEST
FACTORS AFFECTING TIME TO ENGRAFTMENT AND TRANSPLANT
TOXICITY
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Perez-Albuerne, E.D.4 1Children’s National Medical Center, Washing-
ton, DC; 2Children’s Research Institute, Washington, DC; 3Children’s
NationalMedical Center,Washington, DC; 4Children’s NationalMedical
Center, Washington, DC
Intensive chemotherapy dependent on autologous stem cell trans-
plants (ASCT) is used in many protocols for solid tumors, including
brain tumors, and leukemias. ASCT allow the use of more intensive
chemotherapy and faster neutrophil and platelet recovery. Previous
studies have shown that the time to engraftment ranges from 9-28
days for neutrophils (ANC. 500/microliter). ASCT may also be
followed by engraftment toxicity, including fever, sepsis, shock,
and in rare instances, death. Between January 2001 and June 2009,
92 brain tumor, neuroblastoma, and primitive neuro-ectodermal tu-
mor patients (age 6 months to 27 years at transplant) underwent 186
peripheral blood ASCT at Children’s National Medical Center.
Multivariate analysis was used to determine variables affecting pa-
tient outcome measures (time to engraftment, transplant toxicity,
and time to pre-harvest absolute CD34+ peak). Transplant toxicity
was scored on an ordinal scale based on the severity of transplant-re-
lated complications. Independent variables analyzed included vari-
ables that were patient specific (age, weight, tumor type,
chemotherapy administered, and primary vs relapsed disease) and
those related to the harvest or transplant (WBC and CD34+ counts
prior to transplant and quantity of total nucleated cells and CD34+
cells infused during transplant). All cell counts were normalized to
patient weight.
Results:The time to engraftment post transplant was positively cor-
related with absolute CD34+ cells transfused (p5 0.01) and had
a less significant correlation with totalWBC and CD34% transfused
(p5 0.09). No significant correlation was found between platelet re-
covery and quantity of WBC or CD34+ cells transfused. Transplant
toxicity was significantly less with increasing with CD34+ and
CD34%, and was significantly greater in neuroblastoma patients.
The toxicity was significantly greater in younger patients. The
time to CD34+ recovery pre-harvest was significantly affected by pa-
tient diagnosis, chemotherapy regimen, and primary versus recur-
rent disease.
Conclusions: Infusion of larger numbers of CD34+ cells decreased
time to engraftment and transplant toxicity. In this pediatric popula-
tion, neuroblastoma patients and younger patients had more trans-
plant toxicity.246
A STUDY OF THE BARRIERS PREVENTING ACCESS OF U.S. PEDIATRIC
SICKLE CELL DISEASE PATIENTS TO TECHNOLOGIES THAT FACILITATE
COMPATIBLE SIBLING HEMATOPOIETIC CELL TRANSPLANTATION
Yang, J.C.1, Jae, G.1,2, Rahman, A.A.1, Shen, L.1, Lewkowitz, A.1,
Pearson, A.W.1, Sikorski, M.1, Del Toro, G.1 1Mount Sinai School of
Medicine, New York, NY; 2Columbia University, New York, NY
Children who receive hematopoietic cell transplantation (HCT)
for sickle cell disease (SCD) from an HLA-matched, SCD-free sib-
ling show disease-free survival of at least 85%, yet the majority of
children with SCD do not undergo HCT.
